Proactive Investors - Run By Investors For Investors

PreveCeutical Medical progressing well with fingerprinting cannabis strains

The group has applied its protocol and optimised cannabinoid extraction from two cannabis strains
PreveCeutical Medical progressing well with fingerprinting cannabis strains
PreveCeutical is a health sciences firm developing options for preventive and curative therapies

PreveCeutical Medical Inc (TSX:PREV) (OTCQB:PRVCF) reported good progress in  its soluble gel drug delivery research and development (R&D) program.

It has applied its protocol and optimised cannabinoid extraction from two  cannabis strains provided by the company's licensed producer partner Aurora Cannabis Inc.

Preveceutical's chief research officer Dr. Harendra Parekh said: "This is an important verification of our efforts in reproducibly extracting and identifying cannabinoid and THC-rich fractions from plant material, leading to distinct fingerprints for a given strain."

"We are excited with how the fingerprinting of the cannabis strains is progressing," added PreveCeutical's chairman, chief executive and president Stephen Van Deventer.

"With the CBD Sol-gel formulations and applicator development on track, this brings us one step closer to getting the Sol-gel nose-to-brain delivery system to market."

PreveCeutical said it aims to fingerprint two more cannabis strains by 2019, which will bring the total number of distinct fingerprinted cannabis strains in its target cannabinoid concentration range to five.

The company aims to use the fingerprints to generate a range of cannabinoid-based Sol-gel formulations each with a distinct, well-defined cannabinoid composition profile.

View full PREV profile View Profile

PreveCeutical Medical Inc Timeline

Related Articles

cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
Social media use
April 18 2019
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use